NCT00317603View on ClinicalTrials.gov

Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 1, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2021

Conditions
Breast Cancer
Interventions
BIOLOGICAL

Autologous, Lethally Irradiated Breast Cancer Cells

Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00317603 - Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter